Introduction: Tuberculosis (TB) is a significant health problem in developing countries. There are limited data on TB among end stage renal disease (ESRD) patients on maintenance dialysis in India. Clinical profile and outcome of TB in dialysis were studied. Methods: Retrospective study of ESRD patients who were on maintenance dialysis (either peritoneal dialysis [PD] or hemodialysis (HD]) and diagnosed to have TB over a period of 11 years. Findings: Thirty-two patients had a diagnosis of TB. Mean age of the patients was 50.3 AE13.9 years. The majority (56.2%) of the patients were female. The modality of dialysis was HD in 53.1% and PD in 46.9%. Mean duration of dialysis at the diagnosis of TB was 15.1 AE 13.9 months. Over three-quarter of the patients had an extrapulmonary involvement. Pleuro-pulmonary (40.6%), peritoneum (34.4%), and lymph node (15.6%) were the most common sites for TB. About 6.3%patients had disseminated TB, and 3.1% had pericardial TB. The clinical presentation of TB was: fever/pyrexia of unknown origin 28.1%, constitutional symptoms of anorexia, fever, night sweats and weight loss 34.4%, abnormal chest radiograph 37.5%, ascites/peritonitis 34.4%, pleural effusion 25%, lymphadenopathy 18.8%, meningoencephalitis 6.3%, and pericardial effusion 3.1%. Peritoneal TB presented as nonresolving peritonitis in PD and ascites in HD. The diagnosis was a microbiological/histological in 50% and rest 50% only on clinical grounds. Nine (29%) patients had adverse effects of anti-TB drugs. Four patients of TB peritonitis had a poor gastrointestinal tolerance of anti-TB drugs and defaulted on the treatment and had an adverse outcome. About 53.1% of the patients survived, and 46.9% died. Discussion: TB in dialysis is mostly extrapulmonary. Early diagnosis is difficult, and the adverse effects of anti-TB medications complicate the treatment. TB in dialysis carries high morbidity and mortality. TB peritonitis has a poor prognosis.
INTRODUCTION
Tuberculosis (TB) is a significant public health problem and a leading cause of infectious morbidity and mortality worldwide. India is a country with the highest burden of TB in the world. 1 Active TB is an infectious complication that may develop and result from the progression of Mycobacterium tuberculosis infection after the recent exposure or reactivation of latent tuberculosis infection from a remote exposure, often years before the disease develops. Patients receiving dialysis therapy are known to be at increased risk of TB due to an impaired cell-mediated immune response that is responsible for the killing of intracellular organisms such as M. tuberculosis. 2, 3 The clinical manifestations of TB in patients on dialysis are quite nonspecific, making timely diagnosis difficult, and delaying the initiation of curative treatment. The prognosis is very guarded.
Hemodialysis (HD) is the primary modality of maintenance dialysis worldwide. In India, HD used to be mainly a short-term measure to support the end stage renal disease (ESRD) patient for transplantation. However, during the last decade, the number of patients on maintenance HD has increased due increase in the number of dialysis units and improvement in the economic standards. Despite being available for more than 25 years, peritoneal dialysis (PD) is limited in its growth because of economic factors, inadequate government policies, and nephrologist bias; lack of adequate predialysis care; and absence of a self-care culture. The number of patients initiated on PD therapy has also increased in recent years. 5 Various studies across the world have reported TB in dialysis patients, 4, [6] [7] [8] [9] but there are limited data among ESRD patients on maintenance dialysis in India. Therefore, we studied the clinical spectrum and outcome of TB in dialysis at our hospital.
MATERIAL AND METHODS
It was a retrospective study of ESRD patients who were on maintenance dialysis either PD or HD and diagnosed to have TB over a period of 11 years (January 2006 to December 2016) at a tertiary care hospital. We analyzed the clinical and laboratory features at the time of TB diagnosis including epidemiological characteristics and signs suggestive of a pulmonary or extrapulmonary involvement. Diagnosis of TB was on the following criteria: (1) positive direct microscopy or culture of any specimen or tissue for Mycobacterium tuberculosis and (2) histopathological evidence of M. tuberculosis (granulomatous with caseating necrosis). In cases without bacteriological or pathological confirmation, TB was defined as clinical (unexplained fever, impaired general condition), biological (high C-reactive protein [CRP] , hypoalbuminemia, lymphocyte predominance, and exudative effusion of peritoneal, pericardial, and pleural fluid), imaging (pleural lesions, pulmonary lesions) and/or histopathological (noncaseating granulomas), and/or positive tuberculin skin test (TST) and/or history of active TB, and the exclusion of other disease. Half of the patients had a proven TB diagnosis, and it was presumptive in another half. The treatment was with a standard four-drug regimen of anti-TB drugs. Rifampicin and isoniazid were administered daily with 40 mg of pyridoxine for 6 months, whereas ethambutol and pyrazinamide administered on alternate days for the initial 2 months. Adverse effects of therapy and outcome were noted. The institutional ethical committee approved the study.
RESULTS
Thirty-two patients had a diagnosis of TB over the study period. Mean age of the patients was 50.3 AE 13.9 (range: 25-78) years. Fourteen (43.8%) patients were male, and 18 (56.2%) were female. Causes of ESRD were as follows: diabetic nephropathy and hypertension 8 (25%) each, chronic glomerulonephritis 7 (21.9%), and chronic tubulointerstitial nephritis 9 (28.1%). Seventeen (53.1%) patients were in HD, and 15 (46.9%) patients were in PD. The mean duration of dialysis at the diagnosis of TB was 15.1 AE 13.9 months (Table 1) . Two patients had suffered from TB in the past. Table 2 shows the site of TB in these patients. The majority of the patients (78.1%) had extrapulmonary TB. Pleuro-pulmonary 13 (40.6%) and peritoneal 11 (34.4%) were the most common sites for TB. Five (15.6%) patients had lymph nodal TB. Two (6.3%) patients had disseminated TB with central nervous system (CNS) involvement, and one (3.1%) patient had pericardial TB. In PD patients, peritoneal (46.7%) and pleuro-pulmonary (40%) were the main sites of TB. Pleuro-pulmonary (41.2%) followed by peritoneum and lymph node (23.5% each) were the sites of TB in The clinical presentations of TB were as follows: fever/pyrexia of unknown origin 9 (28.1%); constitutional symptoms of anorexia, fever, night sweats, and weight loss 11 (34.4%); abnormal chest radiograph 12 (37.5%); ascites/peritonitis 11 (34.4%); pleural effusion 8 (25%); lymphadenopathy 6 (18.8%); meningoencephalitis 2 (6.3%); and pericardial effusion 1 (3.1%) ( Table 3 ). Peritoneal TB in PD patients had a presentation as nonresolving peritonitis whereas in HD patients it had presented as ascites. The mean erythrocyte sedimentation rate was 82 AE 26 (range: 45-130) mm first hour. Four patients each had pleural effusion on the right and the left sides. The mean levels of adenosine deaminase in pleural fluids and peritoneal fluids were 37 AE 27 and 58 AE 30 IU/L, respectively. The diagnosis was a microbiological/histological in 16 (50%) patients; 11 microbial, four histological, and one both microbiological plus histological. The determination in the other 16 (50%) patients was on clinical grounds. Except for one patient with a post-mortem TB diagnosis, the treatment was with a 6-month course of anti TB drug therapy (ATT) of rifampicin, isoniazid, ethambutol, pyrazinamide, and pyridoxine in all the patients.
Of the 15 patients with PD, one had a post-mortem diagnosis as the culture report came after the demise of the patient. Two patients had catheter removal and were switched to HD due to persistent peritonitis with cloudy PD fluid while five patients continued with PD.
Nine (29%) patients had adverse effects of anti-TB drugs (Table 4 ). Four patients with TB peritonitis had a poor gastrointestinal tolerance to the ATT and defaulted on the treatment. They experienced gastrointestinal side effects in the form of recurrent nausea and vomiting in relations to the intake of anti-TB drugs. They developed an aversion to food that led them to stop the anti-TB drugs. However, none of them had evidence of hepatitis. One patient developed severe hepatitis requiring a temporary stoppage of ATT and three patients experienced an asymptomatic rise in liver enzymes. One patient developed neuropsychiatric symptoms which resolved after a temporary stoppage of isoniazid and increasing pyridoxine to 100 mg/day.
Five patients with TB peritonitis had an adverse outcome. Two PD patients who were switched to HD survived. Overall, 17 (53.1%) patients completed the treatment and recovered. Fifteen (46.9%) patient died. Nine (60%) PD and six (35.3%) HD patients died (P = 0.287). Eight (50%) patients with confirmed TB and seven (43.8%) patients with a presumptive TB diagnosis died (P = 1.000). Except one with a post-mortem TB diagnosis, all the patients died while on ATT.
DISCUSSION
Infections remain a significant cause of morbidity and mortality in patients on dialysis. India continues to have the highest number of tuberculosis cases in the world. Our study is the first study from this TB endemic country reporting clinical spectrum and outcome of TB among maintenance dialysis over a period of 11 years.
Patients with ESRD undergoing chronic dialysis are 6-52.5 times more likely to develop TB than the general population, mainly because of the impaired cellular immunity characteristic of this condition.
5,6,9-12 Impaired cellular immunity suppresses the mitogenic response of lymphocytes. Protein malnutrition, zinc and pyridoxine Gastrointestinal side effects n (%) 4 (12.9) Hepatotoxicity Severe hepatitis n (%) 1 (3.2) Mild hepatitis n (%) 3 (9.7) Neuropsychiatric side effects n (%) 1 (3.2) Total n (%)
9 (29) deficiency, and defects in leukocyte function following exposure to dialysis membranes increase the susceptibility of dialysis patients to TB. 6, 11 However, socioeconomic, demographic, and comorbid factors also predispose these patients to the risk of TB. 3 Mean age of patients reported to develop TB on dialysis being 41.5-73 years. 1, 3, 7, 8, 13 TB tends to occur between 12 and 15 months on dialysis. 7, 13 Over three-quarter of the patients had extrapulmonary involvement. Pleuro-pulmonary (40.6%), peritoneum (34.4%), and lymph node (15.6%) were the most common sites for TB. Extrapulmonary TB in dialysis has been reported to be between 51.6% and 100%. 4, 7, 8, [13] [14] [15] [16] The most common forms of presentation are lymphadenitis, gastrointestinal, bone, genitourinary, peritonitis, pleural effusion, pericardial effusion, miliary TB, and pyrexia of unknown origin (PUO). [17] [18] [19] [20] TB can present as PUO in 43.3%-77.4% patients in endemic areas. [13] [14] [15] [16] [17] [18] [19] [20] Therefore, dialysis patients who present with PUO should be carefully evaluated for the presence of TB, and test therapy for TB should be performed in otherwise unexplained PUO.
In PD patients, peritoneal (46.7%) and pleuropulmonary (40%) were the main types of TB. Pleuropulmonary (41.2%) followed by peritoneum and lymph node (23.5% each) were the sites of TB in HD. Extrapulmonary TB was more common in HD as compared to PD. Presentation of peritoneal TB can differ between PD and HD as was observed in our study. PD patients had nonresolving peritonitis whereas in HD patients presented as ascites. Peritoneal TB carries a high mortality in PD and can often pose a diagnostic challenge to attending clinicians. As TB peritonitis makes up a large part of the TB cases in PD, clinicians should have a high index of suspicion for TB peritonitis in PD patients with features of peritonitis who do not respond promptly to conventional antimicrobial agents. Our patients who continued PD in a setting of TB peritonitis experienced gastrointestinal side effects of anti-TB drugs and defaulted on treatment and died. That suggests against continuing PD after the diagnosis of TB peritonitis and favor switch to HD. However, mortality can still be high in TB peritonitis even if patients are switched to HD. 9 Pleural and lymph node TB were the next most common cause sites of extrapulmonary TB after the peritoneum. TB is a common cause of pleural effusion in dialysis. TB and uremia are the leading cause of exudative pleural effusion among dialysis patients. Differentiating TB from uremic effusion requires a combined clinico-pathological approach, and this differentiation is necessary for proper management. 21 In high-burden settings, the diagnosis is frequently inferred in patients who present with a lymphocytic predominant exudate and a high adenosine deaminase level, which is a valuable adjunct in the diagnostic evaluation. 21 Lymph node TB was considered the most common form of extrapulmonary TB. Recent studies place lymph node TB on the second position in frequency after the pleural TB among HIV-negative patients, while, in patients with HIV/AIDS, it has been determined to be at first position of extrapulmonary TB. 22 Microbiological diagnosis of TB in dialysis ranges from 19.2% to 42%, 2, 4, 6, 8, 23, 24 and histological diagnosis range from 22.7% to 67.1%. 4, 6, 8, 15, 23 The clinical diagnosis of TB has been reported in 28%-48.5% of the patients in various studies. 4, 6, 8, 23 TB diagnosis was on clinical grounds in half of our study patients. TB diagnosis is more complicated and confusing in dialysis patients. There is an increased frequency of extrapulmonary TB, the clinical presentation is atypical, and symptoms and findings are nonspecific. This atypical presentation may often lead to a delay in accurate diagnosis and therapy, sometimes resulting in patients' death. Therefore, physicians should always have a high degree of suspicion and consider the possibility of TB whenever confronted with dialysis patients presenting with general symptoms such as fever, weight loss, and lymphadenopathy. The diagnosis would then require the isolation of acid-fast bacilli, the finding of a typical caseating granuloma on biopsy, or the recovery of tubercle bacilli from the culture of the biopsy material.
Treatment of TB in dialysis is difficult and challenging. There is a high incidence of side effects from anti-TB drugs, especially neuropsychiatric, hepatic, and gastrointestinal. In dialysis, the reported frequency of adverse effects of anti-TB treatment ranges from 46.3% to 56%. 4, 15 The rate of adverse effects of anti-TB drugs was 29% in our patients. A lower frequency of adverse effects observed in our study was because the treatment of patients was with a due dose modification of the anti-TB drugs. Careful monitoring for side-effects is essential in this group, and consideration should be to administer anti-TB chemoprophylaxis to those patients with a positive TST and radiograph suggestive of old TB. TB chemoprophylaxis has been found to be safe and effective in dialysis. 25 TB in dialysis has a poor prognosis and high mortality due to delay in diagnosis and adverse effects of anti-TB drugs. A mortality rate of 14.3%-36.8% has been reported among TB in dialysis. 4, 7, 8, 23 About half of our TB patients died. All except one died while on anti-TB drug therapy.
In conclusion, TB in dialysis patients carries high morbidity and mortality. There is a high frequency of extrapulmonary TB. Therefore, a high index of suspicion for early diagnosis and treatment is required. Adverse effects of anti-TB medications complicate the treatment. TB peritonitis has a poor prognosis. There is a great need for establishing a screening scheme for TB among dialysis patients, and further epidemiological studies are needed to evaluate this problem adequately.
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